topoisomerase inhibitor resistance
DualityBio, Genentech Team Up on Next-Gen ADC Payloads
DualityBio Inc. (HKEX: 09606) announced on August 28 that it has entered a collaboration and license agreement with Genentech, a member of the Roche Group, to develop next-generation antibody-drug conjugates (ADCs) built on DualityBio’s proprietary DUPAC payload platform. Unlike several recent biotech licensing deals that disclosed no financial terms, this one comes with real numbers:…
